Alnylam's Priced for Perfection Party, and the Bouncer Just Checked IDs

Here's the thing about a stock that's up 82% year-over-year on revenue but down nearly 25% year-to-date on price: somebody's math isn't matching somebody else's mood. With Alnylam, that split personality is about to get resolved — one way or another — before the market opens on July 30.

Let's start with what's actually working, because there's a lot of it. Q1 2026 revenue hit $1.167 billion, a step-change from the $774 million trough just three quarters earlier. TTM sales are $4.29 billion, up 82.6% year-over-year. The company flipped from loss-maker to genuinely profitable — $206 million net income, 17.6% net margin, 23% operating margin — on the back of a TTR franchise that is now, by any measure, dominant. Gross margins sit north of 80%. This is not a "someday" biotech story anymore. This is a commercial company with real cash flow and a pipeline still stacked with optionality in Alzheimer's (mivelsiran, ALN‑5288), obesity, dyslipidemia, and beyond.

And then there's the gift nobody at Alnylam had to lift a finger for: on July 9, AstraZeneca and Ionis's Wainua failed its Phase 3 ATTR‑CM readout. That was the one legitimate threat to AMVUTTRA's turf in a franchise management is guiding toward $4.4–4.7 billion in 2026 revenue. Competitor stumbles are the best kind of catalyst — free, structural, and durable. The market responded appropriately at first, sending the stock from ~$320 to $360 in a hurry. Morgan Stanley bumped its target to $400. Chatter puts Raymond James at $468, H.C. Wainwright (before its own trim) at $485. Consensus sits around $446 with a recommendation score near "strong buy."

So why is the stock sitting at $298, having round-tripped almost the entire spike and given back most of the good news in about three weeks?

Because valuation doesn't care about narrative, it cares about denominators. ALNY trades at roughly 75x trailing earnings, 9.3x sales, and 49x EV/EBITDA. Even the friendlier forward P/E of ~22x — based on consensus EPS of $13.50 — assumes 40%+ growth just keeps happening, quarter after quarter, without a hiccup. That's not a valuation that leaves room for "pretty good." It demands "flawless." And a balance sheet with debt/equity north of 2.7x and an ROE above 90% that's flattered more by a thin equity base than by operational magic isn't exactly a fortress you can hide behind if guidance wobbles.

Layer on the technicals and the picture gets more interesting, not less. The daily chart shows ALNY still down nearly 40% from its January highs above $475, hovering just 9% above the 52-week low of $273.11. That $273–282 zone isn't decoration — it's the line in the sand. Break it, and the "buy the dip" thesis is dead on arrival. SMAs are flat, RSI is a boring 48.7, and — this is the part I can't unsee — the longer-range forecast models are actually pointing down toward $228. I don't put full faith in that number, its own track record is mediocre, but when a stock that just got a legitimate competitive tailwind can't hold a bounce, the tape is telling you something the headlines aren't.

Here's my actual take: the fundamental story here is genuinely good, maybe the best it's been in Alnylam's history as a commercial company. But "genuinely good" and "already in the price" are not mutually exclusive, and right now they're roommates. The $250 million manufacturing investment and the reported $2 billion Inceptive AI collaboration are ambitious, but ambition eats free cash flow, and free cash flow has already been lumpy ($49M in Q1 vs. $313M in Q3'25).

My read: this is a name to accumulate on weakness, not chase into strength, and definitely not a name to load up on the night before an earnings print that's genuinely binary. The Wainua failure bought Alnylam a competitive moat. The July 30 print will decide whether the market believes the moat is worth 75 times earnings — or whether $273 becomes the next headline number instead of $475.

Watch the print. Watch $273. Everything else is noise dressed up as conviction.